Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 7, 2026International Journal of Molecular SciencesOpen Access

Clinical Outcomes and Exploratory Longitudinal CTL/Vβ Repertoire Remodeling in Patients with Relapsed or Refractory Large B-Cell Lymphoma and Follicular Lymphoma Treated with Epcoritamab

View Full Paper
Ask AI
Bookmark
Share

Authors

TJTatsuro JoJTJun TaguchiYSYasushi Sawayama

Discussion

Loading...

Member takes

Overview

Randomized trial analyzes clinical outcomes and immune patterns in patients with relapsed lymphoma, suggesting implications for treatment success.

Key Points

  • To evaluate the clinical outcomes and immune correlates associated with epcoritamab in relapsed or refractory B-cell lymphomas.
  • Retrospective analysis of 21 patients with relapsed or refractory large B-cell lymphoma and follicular lymphoma treated with epcoritamab.
  • Evaluated overall response rates and conducted serial analyses of CTL subsets and TCR Vβ repertoire.
  • Clinical follow-up extended until May 2026.
  • Overall response rate was 64% (9/14) in large B-cell lymphoma and 100% (4/4) in follicular lymphoma.
  • Median overall survival was 431 days for both large B-cell lymphoma and follicular lymphoma.
  • Observations indicated Vβ-skewed CTL populations in cases where treatment was electively discontinued after achieving complete remission.

Cite This Study

Jo et al. (2026) studied this question.

synapsesocial.com/papers/6a250cbc7def13d035e1cd92https://doi.org/10.3390/ijms27115132
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial2026 · 4 citations
  2. 2Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma2025 · 14 citations
  3. 3Activated Memory Cytotoxic T-Lymphocytes and T-Cell Receptor Vβ Clonality Predict Treatment-Free Remission After Tyrosine Kinase Inhibitor Discontinuation in Chronic-Phase Chronic Myeloid Leukemia: A 1-Year Prospective Immuno-Monitoring Study2026 · 3 citations
  4. 4Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells2024 · 10 citations
  5. 5Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial2024 · 142 citations